Chronic Cavitary Pulmonary Histoplasmosis: Is It Becoming Rare in the United States?
Open Forum Infectious Diseases · 13.11.2026
DOI: 10.1093/ofid/ofag718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 13.11.2026. Verfasst von John E Bennett.
Abstract (Originalsprache)
Introduction
Chronic cavitary pulmonary histoplasmosis (CCPH) was widely reported in the United States during the mid-twentieth century but is now rarely described. Whether this reflects a true decline in incidence is uncertain. Because emphysema and cigarette smoking are major predisposing factors, reductions in smoking-related lung disease may have contributed to the apparent decrease.
Methods
We reviewed 13 previously unpublished cases of CCPH managed at the National Institutes of Health between 1960 and 1985. Cases were included when diagnosis was supported by culture, histopathology, or both, together with a compatible chronic clinical and radiographic course. Demographic, clinical, microbiologic, radiographic, treatment, pulmonary function, and follow-up data were analyzed descriptively.
Results
Most patients were men aged 30–60 years, and all but one had a history of substantial cigarette smoking. Common manifestations included productive cough, chest pain, fever or night sweats, weight loss, and hemoptysis. Radiographs typically showed slowly progressive upper-lobe infiltrates with cavitation, fibrosis, pleural thickening, and volume loss, often mimicking tuberculosis. Eight patients had emphysema. Diagnosis was delayed year or more in ten. Four patients initially received antituberculous therapy. Treatment with amphotericin B or ketoconazole arrested microbiologic progression, but radiographic abnormalities and pulmonary impairment often persisted. Morbidity was substantial, and three patients died of pulmonary complications.
Conclusions
This series highlights the characteristic presentation, prolonged course, and major association of CCPH with smoking-related lung disease. Although now rarely reported in the United States, CCPH remains an important and treatable diagnosis that should be considered in patients with chronic upper-lobe fibrocavitary disease, especially in endemic regions.
Zitieren
APA
Bennett, J. E. (2026). Chronic Cavitary Pulmonary Histoplasmosis: Is It Becoming Rare in the United States?. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofag718
Vancouver
Bennett JE. Chronic Cavitary Pulmonary Histoplasmosis: Is It Becoming Rare in the United States?. Open Forum Infectious Diseases. 2026. doi:10.1093/ofid/ofag718
BibTeX
@article{Bennett2026,
author = {Bennett, John E},
title = {Chronic Cavitary Pulmonary Histoplasmosis: Is It Becoming Rare in the United States?},
journal = {Open Forum Infectious Diseases},
year = {2026},
doi = {10.1093/ofid/ofag718}
}
EUVIMED